Owners are increasingly seeking high-quality veterinary care for their pets. Dogs get cancer at roughly the same rate as humans and the disease accounts for almost half of the deaths of pets over 10 years of age[i].
There are over 180 million dogs and cats in the US[ii] and almost 190 million in Europe[iii] and the American Pet Products Association estimates that the US market for veterinary services was worth USD 15.9 billion in 2016.
Oasmia is currently exploring strategic options for its Animal Health portfolio. [If you are interested in finding out more about the applications of our technology in Animal Health, please contact firstname.lastname@example.org].
[ii] National Pet Owners Survey (2017–2018), APPA.
[iii] Facts & Figures (2017), the European Pet Food Industry Federation
90 million dogs
There were approximately 90 million dogs in the US 2017 and in Europe the corresponding number was 87,5 million1
dog insurance is USD 47
In the US, the average monthly cost for a dog insurance is USD 472
estimated at USD 33 billion
The value of US veterinary services market in 2017 was estimated at USD 33 billion3
Oasmia’s product candidates within veterinary medicine use the XR-17 technology platform to facilitate the administration of intravenously delivered solvent-free active pharmaceutical ingredients. Oasmia’s development work focuses on the creation of new formulations of wellestablished chemotherapy drugs that may be usable for the treatment of cancer in pets. Oasmia currently has two product candidates within veterinary oncology: Doxophos Vet and Paccal Vet. Both product candidates are in the clinical phase and require additional investments before regulatory approval can be granted.
Paccal vet (paclitaxel)
Doxophos vet (doxorubicin)
Paccal Vet utilizes Oasmia’s formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The development program for Paccal Vet is currently on hold, awaiting further strategic decisions.
Doxophos Vet is a patented formulation of doxorubicin, one of the most efficacious and widely used chemotherapeutic substances for the treatment of cancer. Oasmia has developed Doxophos Vet for the treatment of lymphoma, one of the most frequent forms of canine cancer. Pre-clinical and earlier clinical studies have been conducted on dogs with cancer. In the first attempt, Doxophos Vet showed promising efficacy against hematological tumors. The development program is currently on hold, awaiting further strategic decisions.